nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—ADRB3—polycystic ovary syndrome	0.403	0.586	CbGaD
Isoprenaline—ADRB2—polycystic ovary syndrome	0.153	0.223	CbGaD
Isoprenaline—CYP1A1—polycystic ovary syndrome	0.131	0.191	CbGaD
Isoprenaline—PIK3R2—female gonad—polycystic ovary syndrome	0.00383	0.0467	CbGeAlD
Isoprenaline—PIK3R2—endocrine gland—polycystic ovary syndrome	0.00356	0.0435	CbGeAlD
Isoprenaline—PIK3R3—endometrium—polycystic ovary syndrome	0.00345	0.0421	CbGeAlD
Isoprenaline—PIK3R1—adrenal cortex—polycystic ovary syndrome	0.0033	0.0402	CbGeAlD
Isoprenaline—PIK3R3—uterus—polycystic ovary syndrome	0.00317	0.0388	CbGeAlD
Isoprenaline—PIK3R3—pituitary gland—polycystic ovary syndrome	0.00312	0.0381	CbGeAlD
Isoprenaline—PIK3R3—adipose tissue—polycystic ovary syndrome	0.0031	0.0379	CbGeAlD
Isoprenaline—PIK3R1—endometrium—polycystic ovary syndrome	0.00294	0.0359	CbGeAlD
Isoprenaline—PIK3R3—adrenal gland—polycystic ovary syndrome	0.00279	0.034	CbGeAlD
Isoprenaline—ADRBK1—embryo—polycystic ovary syndrome	0.00278	0.034	CbGeAlD
Isoprenaline—MAPK1—embryo—polycystic ovary syndrome	0.00274	0.0335	CbGeAlD
Isoprenaline—PIK3R1—uterus—polycystic ovary syndrome	0.00271	0.0331	CbGeAlD
Isoprenaline—PIK3R1—pituitary gland—polycystic ovary syndrome	0.00266	0.0325	CbGeAlD
Isoprenaline—PIK3R1—adipose tissue—polycystic ovary syndrome	0.00265	0.0324	CbGeAlD
Isoprenaline—PIK3R3—female gonad—polycystic ovary syndrome	0.0026	0.0317	CbGeAlD
Isoprenaline—PIK3R3—vagina—polycystic ovary syndrome	0.00258	0.0315	CbGeAlD
Isoprenaline—PIK3R3—endocrine gland—polycystic ovary syndrome	0.00242	0.0295	CbGeAlD
Isoprenaline—PIK3R1—adrenal gland—polycystic ovary syndrome	0.00238	0.029	CbGeAlD
Isoprenaline—PIK3R1—female gonad—polycystic ovary syndrome	0.00222	0.0271	CbGeAlD
Isoprenaline—PIK3R1—vagina—polycystic ovary syndrome	0.0022	0.0269	CbGeAlD
Isoprenaline—ADRB3—adipose tissue—polycystic ovary syndrome	0.00188	0.0229	CbGeAlD
Isoprenaline—MAPK1—uterus—polycystic ovary syndrome	0.00185	0.0226	CbGeAlD
Isoprenaline—ADRBK1—adipose tissue—polycystic ovary syndrome	0.00184	0.0224	CbGeAlD
Isoprenaline—MAPK1—adipose tissue—polycystic ovary syndrome	0.00181	0.0221	CbGeAlD
Isoprenaline—ADRBK1—adrenal gland—polycystic ovary syndrome	0.00165	0.0201	CbGeAlD
Isoprenaline—MAPK1—adrenal gland—polycystic ovary syndrome	0.00162	0.0198	CbGeAlD
Isoprenaline—ADRB3—female gonad—polycystic ovary syndrome	0.00157	0.0192	CbGeAlD
Isoprenaline—ADRBK1—female gonad—polycystic ovary syndrome	0.00153	0.0187	CbGeAlD
Isoprenaline—ADRBK1—vagina—polycystic ovary syndrome	0.00153	0.0186	CbGeAlD
Isoprenaline—MAPK1—female gonad—polycystic ovary syndrome	0.00151	0.0185	CbGeAlD
Isoprenaline—MAPK1—vagina—polycystic ovary syndrome	0.0015	0.0184	CbGeAlD
Isoprenaline—ADRBK1—endocrine gland—polycystic ovary syndrome	0.00143	0.0174	CbGeAlD
Isoprenaline—MAPK1—endocrine gland—polycystic ovary syndrome	0.00141	0.0172	CbGeAlD
Isoprenaline—ADRB1—adipose tissue—polycystic ovary syndrome	0.000768	0.00937	CbGeAlD
Isoprenaline—ADRB1—endocrine gland—polycystic ovary syndrome	0.000597	0.00729	CbGeAlD
Isoprenaline—CYP1A1—uterus—polycystic ovary syndrome	0.000506	0.00618	CbGeAlD
Isoprenaline—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000495	0.00605	CbGeAlD
Isoprenaline—Fenoterol—ADRB3—polycystic ovary syndrome	0.000457	0.0603	CrCbGaD
Isoprenaline—Phenylephrine—ADRA1D—polycystic ovary syndrome	0.000449	0.0593	CrCbGaD
Isoprenaline—Arbutamine—ADRB3—polycystic ovary syndrome	0.000428	0.0564	CrCbGaD
Isoprenaline—CYP1A1—female gonad—polycystic ovary syndrome	0.000414	0.00506	CbGeAlD
Isoprenaline—CYP1A1—vagina—polycystic ovary syndrome	0.000412	0.00503	CbGeAlD
Isoprenaline—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000385	0.0047	CbGeAlD
Isoprenaline—Phenylephrine—ADRA1B—polycystic ovary syndrome	0.000383	0.0506	CrCbGaD
Isoprenaline—Orciprenaline—ADRB2—polycystic ovary syndrome	0.000323	0.0427	CrCbGaD
Isoprenaline—Labetalol—ADRB3—polycystic ovary syndrome	0.000303	0.04	CrCbGaD
Isoprenaline—Pindolol—ADRB3—polycystic ovary syndrome	0.000291	0.0384	CrCbGaD
Isoprenaline—Droxidopa—ADRA1D—polycystic ovary syndrome	0.000273	0.0361	CrCbGaD
Isoprenaline—Phenylephrine—ADRA1A—polycystic ovary syndrome	0.000258	0.0341	CrCbGaD
Isoprenaline—Droxidopa—ADRB3—polycystic ovary syndrome	0.000246	0.0324	CrCbGaD
Isoprenaline—Droxidopa—ADRA1B—polycystic ovary syndrome	0.000233	0.0308	CrCbGaD
Isoprenaline—Norepinephrine—ADRA1D—polycystic ovary syndrome	0.00023	0.0304	CrCbGaD
Isoprenaline—Levonordefrin—ADRA1A—polycystic ovary syndrome	0.000223	0.0294	CrCbGaD
Isoprenaline—Terbutaline—ADRB2—polycystic ovary syndrome	0.000212	0.028	CrCbGaD
Isoprenaline—Epinephrine—ADRA1D—polycystic ovary syndrome	0.000209	0.0276	CrCbGaD
Isoprenaline—Norepinephrine—ADRB3—polycystic ovary syndrome	0.000207	0.0273	CrCbGaD
Isoprenaline—Isoetarine—ADRB2—polycystic ovary syndrome	0.000204	0.027	CrCbGaD
Isoprenaline—Masoprocol—CYP19A1—polycystic ovary syndrome	0.000198	0.0261	CrCbGaD
Isoprenaline—Sotalol—ADRB2—polycystic ovary syndrome	0.000197	0.0261	CrCbGaD
Isoprenaline—Norepinephrine—ADRA1B—polycystic ovary syndrome	0.000196	0.0259	CrCbGaD
Isoprenaline—Epinephrine—ADRB3—polycystic ovary syndrome	0.000188	0.0248	CrCbGaD
Isoprenaline—Epinephrine—ADRA1B—polycystic ovary syndrome	0.000178	0.0235	CrCbGaD
Isoprenaline—Fenoterol—ADRB2—polycystic ovary syndrome	0.000174	0.0229	CrCbGaD
Isoprenaline—Arbutamine—ADRB2—polycystic ovary syndrome	0.000163	0.0215	CrCbGaD
Isoprenaline—Arformoterol—ADRB2—polycystic ovary syndrome	0.000158	0.0208	CrCbGaD
Isoprenaline—Formoterol—ADRB2—polycystic ovary syndrome	0.000158	0.0208	CrCbGaD
Isoprenaline—Salbutamol—ADRB2—polycystic ovary syndrome	0.000158	0.0208	CrCbGaD
Isoprenaline—Droxidopa—ADRA1A—polycystic ovary syndrome	0.000157	0.0207	CrCbGaD
Isoprenaline—Norepinephrine—ADRA1A—polycystic ovary syndrome	0.000132	0.0174	CrCbGaD
Isoprenaline—Epinephrine—ADRA1A—polycystic ovary syndrome	0.00012	0.0158	CrCbGaD
Isoprenaline—Labetalol—ADRB2—polycystic ovary syndrome	0.000115	0.0152	CrCbGaD
Isoprenaline—Pindolol—ADRB2—polycystic ovary syndrome	0.000111	0.0146	CrCbGaD
Isoprenaline—Droxidopa—ADRB2—polycystic ovary syndrome	9.34e-05	0.0123	CrCbGaD
Isoprenaline—Norepinephrine—ADRB2—polycystic ovary syndrome	7.86e-05	0.0104	CrCbGaD
Isoprenaline—Epinephrine—ADRB2—polycystic ovary syndrome	7.13e-05	0.00941	CrCbGaD
Isoprenaline—MAPK1—Disease—PRL—polycystic ovary syndrome	7.7e-06	3.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.64e-06	3.43e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GNRH1—polycystic ovary syndrome	7.62e-06	3.42e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—YAP1—polycystic ovary syndrome	7.61e-06	3.41e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—SERPINE1—polycystic ovary syndrome	7.56e-06	3.39e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IRS1—polycystic ovary syndrome	7.55e-06	3.39e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	7.55e-06	3.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IRS1—polycystic ovary syndrome	7.54e-06	3.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—CYP1A1—polycystic ovary syndrome	7.53e-06	3.38e-05	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	7.53e-06	3.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—BCL2—polycystic ovary syndrome	7.53e-06	3.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.52e-06	3.37e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—GAB1—polycystic ovary syndrome	7.51e-06	3.37e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SCT—polycystic ovary syndrome	7.47e-06	3.35e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.46e-06	3.34e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—SERPINE1—polycystic ovary syndrome	7.45e-06	3.34e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—BCL2—polycystic ovary syndrome	7.41e-06	3.32e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	7.38e-06	3.31e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	7.38e-06	3.31e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	7.37e-06	3.3e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.34e-06	3.29e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SCT—polycystic ovary syndrome	7.31e-06	3.28e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—POMC—polycystic ovary syndrome	7.27e-06	3.26e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—INS—polycystic ovary syndrome	7.23e-06	3.24e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—INSR—polycystic ovary syndrome	7.18e-06	3.22e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—HMMR—polycystic ovary syndrome	7.13e-06	3.2e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	7.13e-06	3.2e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—BCL2—polycystic ovary syndrome	7.12e-06	3.19e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—PPARG—polycystic ovary syndrome	7.03e-06	3.15e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—MTHFR—polycystic ovary syndrome	7.02e-06	3.15e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL18—polycystic ovary syndrome	7.01e-06	3.14e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—FGF18—polycystic ovary syndrome	7.01e-06	3.14e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IGF1—polycystic ovary syndrome	6.99e-06	3.14e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—AKT2—polycystic ovary syndrome	6.99e-06	3.13e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—AKT2—polycystic ovary syndrome	6.98e-06	3.13e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—GNAS—polycystic ovary syndrome	6.97e-06	3.13e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	6.97e-06	3.13e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—IRS1—polycystic ovary syndrome	6.96e-06	3.12e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—RBP4—polycystic ovary syndrome	6.95e-06	3.11e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—POMC—polycystic ovary syndrome	6.93e-06	3.11e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IRS2—polycystic ovary syndrome	6.89e-06	3.09e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—INS—polycystic ovary syndrome	6.89e-06	3.09e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cellular responses to stress—IL6—polycystic ovary syndrome	6.89e-06	3.09e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—NRG1—polycystic ovary syndrome	6.86e-06	3.07e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—FGF18—polycystic ovary syndrome	6.85e-06	3.07e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—GNAS—polycystic ovary syndrome	6.84e-06	3.07e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	6.82e-06	3.06e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—GNAS—polycystic ovary syndrome	6.81e-06	3.05e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—HSD3B1—polycystic ovary syndrome	6.81e-06	3.05e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—RBP4—polycystic ovary syndrome	6.8e-06	3.05e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IRS2—polycystic ovary syndrome	6.79e-06	3.05e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—LEP—polycystic ovary syndrome	6.75e-06	3.03e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	6.73e-06	3.02e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	6.71e-06	3.01e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—GNAS—polycystic ovary syndrome	6.69e-06	3e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Innate Immune System—IL6—polycystic ovary syndrome	6.69e-06	3e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—INS—polycystic ovary syndrome	6.67e-06	2.99e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—LEP—polycystic ovary syndrome	6.65e-06	2.98e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PGR—polycystic ovary syndrome	6.64e-06	2.98e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.64e-06	2.98e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.64e-06	2.98e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Innate Immune System—IL6—polycystic ovary syndrome	6.59e-06	2.95e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cytokine Signaling in Immune system—IL6—polycystic ovary syndrome	6.57e-06	2.95e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—NRG1—polycystic ovary syndrome	6.52e-06	2.92e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.49e-06	2.91e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—YAP1—polycystic ovary syndrome	6.49e-06	2.91e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by NGF—IL6—polycystic ovary syndrome	6.46e-06	2.9e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—NCOR1—polycystic ovary syndrome	6.45e-06	2.89e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—AKT2—polycystic ovary syndrome	6.45e-06	2.89e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—GAB1—polycystic ovary syndrome	6.4e-06	2.87e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—NRG1—polycystic ovary syndrome	6.37e-06	2.85e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—YAP1—polycystic ovary syndrome	6.34e-06	2.84e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—NRG1—polycystic ovary syndrome	6.33e-06	2.84e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GAB1—polycystic ovary syndrome	6.26e-06	2.81e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—LHB—polycystic ovary syndrome	6.21e-06	2.78e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PLAT—polycystic ovary syndrome	6.18e-06	2.77e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—GHRL—polycystic ovary syndrome	6.18e-06	2.77e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—SERPINE1—polycystic ovary syndrome	6.13e-06	2.75e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—INSR—polycystic ovary syndrome	6.12e-06	2.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—BCL2—polycystic ovary syndrome	6.1e-06	2.73e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—HSD3B2—polycystic ovary syndrome	6.07e-06	2.72e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—VEGFA—polycystic ovary syndrome	6.03e-06	2.7e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IRS1—polycystic ovary syndrome	6.02e-06	2.7e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—INSR—polycystic ovary syndrome	5.98e-06	2.68e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IRS1—polycystic ovary syndrome	5.93e-06	2.66e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—VEGFA—polycystic ovary syndrome	5.92e-06	2.65e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—ATF1—polycystic ovary syndrome	5.89e-06	2.64e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—AKR1C1—polycystic ovary syndrome	5.88e-06	2.63e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IRS2—polycystic ovary syndrome	5.87e-06	2.63e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—CRP—polycystic ovary syndrome	5.87e-06	2.63e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Axon guidance—IL6—polycystic ovary syndrome	5.85e-06	2.62e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	5.81e-06	2.61e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—POMC—polycystic ovary syndrome	5.8e-06	2.6e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—INS—polycystic ovary syndrome	5.76e-06	2.58e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	5.75e-06	2.58e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.72e-06	2.57e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—POMC—polycystic ovary syndrome	5.71e-06	2.56e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MTHFR—polycystic ovary syndrome	5.7e-06	2.56e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—PPARG—polycystic ovary syndrome	5.69e-06	2.55e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	5.68e-06	2.55e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—INS—polycystic ovary syndrome	5.68e-06	2.55e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PGR—polycystic ovary syndrome	5.66e-06	2.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—POMC—polycystic ovary syndrome	5.62e-06	2.52e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	5.6e-06	2.51e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IRS2—polycystic ovary syndrome	5.59e-06	2.5e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—INS—polycystic ovary syndrome	5.59e-06	2.5e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IGF1—polycystic ovary syndrome	5.58e-06	2.5e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—AKT2—polycystic ovary syndrome	5.57e-06	2.5e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PGR—polycystic ovary syndrome	5.54e-06	2.48e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IGF1—polycystic ovary syndrome	5.49e-06	2.46e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—AKT2—polycystic ovary syndrome	5.49e-06	2.46e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—LEP—polycystic ovary syndrome	5.47e-06	2.45e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IRS2—polycystic ovary syndrome	5.45e-06	2.44e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NGFR—polycystic ovary syndrome	5.44e-06	2.44e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IRS2—polycystic ovary syndrome	5.42e-06	2.43e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Innate Immune System—IL6—polycystic ovary syndrome	5.42e-06	2.43e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—SULT2A1—polycystic ovary syndrome	5.41e-06	2.42e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—POMC—polycystic ovary syndrome	5.4e-06	2.42e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PRL—polycystic ovary syndrome	5.39e-06	2.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling by GPCR—IL6—polycystic ovary syndrome	5.35e-06	2.4e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—LEP—polycystic ovary syndrome	5.34e-06	2.39e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.29e-06	2.37e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PLAT—polycystic ovary syndrome	5.26e-06	2.36e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—GHRL—polycystic ovary syndrome	5.26e-06	2.36e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—RRM2—polycystic ovary syndrome	5.24e-06	2.35e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.22e-06	2.34e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—AKT2—polycystic ovary syndrome	5.19e-06	2.33e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PLAT—polycystic ovary syndrome	5.15e-06	2.31e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GHRL—polycystic ovary syndrome	5.15e-06	2.31e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IRS1—polycystic ovary syndrome	5.13e-06	2.3e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—ADRB2—polycystic ovary syndrome	5.11e-06	2.29e-05	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—POMC—polycystic ovary syndrome	5.07e-06	2.27e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	5.05e-06	2.26e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ATF1—polycystic ovary syndrome	5.02e-06	2.25e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—POMC—polycystic ovary syndrome	4.96e-06	2.22e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—ATF1—polycystic ovary syndrome	4.91e-06	2.2e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.9e-06	2.2e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Immune System—IL6—polycystic ovary syndrome	4.89e-06	2.19e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IRS1—polycystic ovary syndrome	4.88e-06	2.19e-05	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.87e-06	2.19e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	4.85e-06	2.17e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.82e-06	2.16e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	4.79e-06	2.15e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	4.79e-06	2.15e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	4.77e-06	2.14e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IRS1—polycystic ovary syndrome	4.76e-06	2.13e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	4.76e-06	2.13e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—AKT2—polycystic ovary syndrome	4.75e-06	2.13e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.74e-06	2.13e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IRS1—polycystic ovary syndrome	4.73e-06	2.12e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—POMC—polycystic ovary syndrome	4.7e-06	2.11e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—INS—polycystic ovary syndrome	4.67e-06	2.09e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NGFR—polycystic ovary syndrome	4.63e-06	2.08e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—POMC—polycystic ovary syndrome	4.61e-06	2.07e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PRL—polycystic ovary syndrome	4.59e-06	2.06e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—POMC—polycystic ovary syndrome	4.58e-06	2.06e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.57e-06	2.05e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—INS—polycystic ovary syndrome	4.56e-06	2.04e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NGFR—polycystic ovary syndrome	4.53e-06	2.03e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—INS—polycystic ovary syndrome	4.53e-06	2.03e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	4.52e-06	2.03e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IGF1—polycystic ovary syndrome	4.52e-06	2.03e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.52e-06	2.03e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.51e-06	2.02e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—IL6—polycystic ovary syndrome	4.51e-06	2.02e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—POMC—polycystic ovary syndrome	4.51e-06	2.02e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PRL—polycystic ovary syndrome	4.49e-06	2.01e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	4.45e-06	2e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NRG1—polycystic ovary syndrome	4.43e-06	1.99e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.43e-06	1.99e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IGF1—polycystic ovary syndrome	4.41e-06	1.98e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—AKT2—polycystic ovary syndrome	4.41e-06	1.98e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—AKT2—polycystic ovary syndrome	4.38e-06	1.96e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.36e-06	1.95e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.33e-06	1.94e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.29e-06	1.92e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—IL6—polycystic ovary syndrome	4.26e-06	1.91e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.2e-06	1.88e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.19e-06	1.88e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—IL6—polycystic ovary syndrome	4.17e-06	1.87e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—SERPINE1—polycystic ovary syndrome	4.16e-06	1.87e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—BCL2—polycystic ovary syndrome	4.15e-06	1.86e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.04e-06	1.81e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GNAS—polycystic ovary syndrome	3.95e-06	1.77e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—IL6—polycystic ovary syndrome	3.9e-06	1.75e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—TH—polycystic ovary syndrome	3.85e-06	1.73e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.85e-06	1.73e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—IL6—polycystic ovary syndrome	3.84e-06	1.72e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.8e-06	1.7e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NRG1—polycystic ovary syndrome	3.78e-06	1.69e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.77e-06	1.69e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	3.75e-06	1.68e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—LEP—polycystic ovary syndrome	3.72e-06	1.67e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NRG1—polycystic ovary syndrome	3.7e-06	1.66e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—IL6—polycystic ovary syndrome	3.68e-06	1.65e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.64e-06	1.63e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—IL6—polycystic ovary syndrome	3.6e-06	1.61e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.59e-06	1.61e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—IL6—polycystic ovary syndrome	3.54e-06	1.59e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	3.52e-06	1.58e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.45e-06	1.55e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—IL6—polycystic ovary syndrome	3.37e-06	1.51e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.32e-06	1.49e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.24e-06	1.45e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—POMC—polycystic ovary syndrome	3.19e-06	1.43e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—INS—polycystic ovary syndrome	3.17e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—LEP—polycystic ovary syndrome	3.17e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.17e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IL6—polycystic ovary syndrome	3.16e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IL6—polycystic ovary syndrome	3.16e-06	1.42e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	3.15e-06	1.41e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—LEP—polycystic ovary syndrome	3.1e-06	1.39e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.07e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.07e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	3e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.95e-06	1.32e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.92e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—IL6—polycystic ovary syndrome	2.91e-06	1.31e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.88e-06	1.29e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IRS1—polycystic ovary syndrome	2.83e-06	1.27e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IRS1—polycystic ovary syndrome	2.76e-06	1.24e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—POMC—polycystic ovary syndrome	2.72e-06	1.22e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—INS—polycystic ovary syndrome	2.71e-06	1.21e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—POMC—polycystic ovary syndrome	2.66e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	2.65e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—INS—polycystic ovary syndrome	2.65e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.62e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.62e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IGF1—polycystic ovary syndrome	2.56e-06	1.15e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKT2—polycystic ovary syndrome	2.56e-06	1.15e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IL6—polycystic ovary syndrome	2.52e-06	1.13e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.49e-06	1.11e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.48e-06	1.11e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.43e-06	1.09e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.35e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	2.15e-06	9.63e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL6—polycystic ovary syndrome	2.15e-06	9.62e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	2.12e-06	9.5e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—INS—polycystic ovary syndrome	2.11e-06	9.44e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL6—polycystic ovary syndrome	2.04e-06	9.15e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.01e-06	8.99e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—IL6—polycystic ovary syndrome	2e-06	8.97e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL6—polycystic ovary syndrome	1.99e-06	8.93e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IL6—polycystic ovary syndrome	1.98e-06	8.88e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL6—polycystic ovary syndrome	1.96e-06	8.78e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.71e-06	7.66e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.67e-06	7.5e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL6—polycystic ovary syndrome	1.39e-06	6.22e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL6—polycystic ovary syndrome	1.18e-06	5.3e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL6—polycystic ovary syndrome	1.16e-06	5.19e-06	CbGpPWpGaD
